nodes	percent_of_prediction	percent_of_DWPC	metapath
Desipramine—SLC22A3—Melphalan—ovarian cancer	0.291	0.606	CbGbCtD
Desipramine—ABCB1—ovarian cancer	0.186	1	CbGaD
Desipramine—ABCB1—Topotecan—ovarian cancer	0.0317	0.0662	CbGbCtD
Desipramine—ABCB1—Vinorelbine—ovarian cancer	0.0224	0.0466	CbGbCtD
Desipramine—CYP2D6—Vinorelbine—ovarian cancer	0.0211	0.0439	CbGbCtD
Desipramine—CYP3A4—Topotecan—ovarian cancer	0.019	0.0397	CbGbCtD
Desipramine—CYP2B6—Doxorubicin—ovarian cancer	0.0165	0.0344	CbGbCtD
Desipramine—ABCB1—Paclitaxel—ovarian cancer	0.0157	0.0328	CbGbCtD
Desipramine—CYP3A4—Vinorelbine—ovarian cancer	0.0134	0.0279	CbGbCtD
Desipramine—ABCB1—Docetaxel—ovarian cancer	0.0114	0.0237	CbGbCtD
Desipramine—CYP3A4—Paclitaxel—ovarian cancer	0.00941	0.0196	CbGbCtD
Desipramine—ABCB1—Doxorubicin—ovarian cancer	0.00847	0.0177	CbGbCtD
Desipramine—CYP2D6—Doxorubicin—ovarian cancer	0.00798	0.0166	CbGbCtD
Desipramine—CHRM3—muscle of abdomen—ovarian cancer	0.00711	0.0949	CbGeAlD
Desipramine—CYP3A4—Docetaxel—ovarian cancer	0.0068	0.0142	CbGbCtD
Desipramine—CYP3A4—Doxorubicin—ovarian cancer	0.00507	0.0106	CbGbCtD
Desipramine—HTR2A—vein—ovarian cancer	0.00325	0.0434	CbGeAlD
Desipramine—SMPD1—decidua—ovarian cancer	0.00215	0.0287	CbGeAlD
Desipramine—SMPD1—gonad—ovarian cancer	0.00189	0.0253	CbGeAlD
Desipramine—CYP2C18—uterine cervix—ovarian cancer	0.00183	0.0245	CbGeAlD
Desipramine—SMPD1—female reproductive system—ovarian cancer	0.00169	0.0226	CbGeAlD
Desipramine—SMPD1—female gonad—ovarian cancer	0.00154	0.0205	CbGeAlD
Desipramine—SMPD1—vagina—ovarian cancer	0.00153	0.0204	CbGeAlD
Desipramine—CHRM5—epithelium—ovarian cancer	0.00151	0.0202	CbGeAlD
Desipramine—SLC22A4—myometrium—ovarian cancer	0.00136	0.0182	CbGeAlD
Desipramine—SMPD1—testis—ovarian cancer	0.00136	0.0182	CbGeAlD
Desipramine—CYP2C18—vagina—ovarian cancer	0.00124	0.0166	CbGeAlD
Desipramine—SLC22A3—myometrium—ovarian cancer	0.00124	0.0166	CbGeAlD
Desipramine—SLC22A3—embryo—ovarian cancer	0.00119	0.016	CbGeAlD
Desipramine—CHRM4—testis—ovarian cancer	0.00116	0.0155	CbGeAlD
Desipramine—SLC22A4—decidua—ovarian cancer	0.00101	0.0135	CbGeAlD
Desipramine—ORM1—endometrium—ovarian cancer	0.000999	0.0133	CbGeAlD
Desipramine—SMPD1—lymph node—ovarian cancer	0.000988	0.0132	CbGeAlD
Desipramine—SLC22A3—uterine cervix—ovarian cancer	0.000967	0.0129	CbGeAlD
Desipramine—SLC22A4—endometrium—ovarian cancer	0.000961	0.0128	CbGeAlD
Desipramine—SLC22A5—myometrium—ovarian cancer	0.000903	0.0121	CbGeAlD
Desipramine—SLC22A3—endometrium—ovarian cancer	0.000874	0.0117	CbGeAlD
Desipramine—ORM1—female reproductive system—ovarian cancer	0.000827	0.0111	CbGeAlD
Desipramine—CYP2A6—vagina—ovarian cancer	0.000821	0.011	CbGeAlD
Desipramine—SLC22A3—gonad—ovarian cancer	0.000811	0.0108	CbGeAlD
Desipramine—SLC22A4—female reproductive system—ovarian cancer	0.000796	0.0106	CbGeAlD
Desipramine—SLC6A2—decidua—ovarian cancer	0.000789	0.0105	CbGeAlD
Desipramine—ORM1—bone marrow—ovarian cancer	0.000781	0.0104	CbGeAlD
Desipramine—HRH1—myometrium—ovarian cancer	0.000766	0.0102	CbGeAlD
Desipramine—SLC22A4—bone marrow—ovarian cancer	0.000751	0.01	CbGeAlD
Desipramine—HTR2C—female reproductive system—ovarian cancer	0.000744	0.00993	CbGeAlD
Desipramine—ADRB1—female reproductive system—ovarian cancer	0.00073	0.00975	CbGeAlD
Desipramine—SLC22A3—female reproductive system—ovarian cancer	0.000724	0.00967	CbGeAlD
Desipramine—SLC22A4—vagina—ovarian cancer	0.00072	0.00961	CbGeAlD
Desipramine—SLC6A4—female reproductive system—ovarian cancer	0.000705	0.00942	CbGeAlD
Desipramine—SLC22A5—uterine cervix—ovarian cancer	0.000703	0.00939	CbGeAlD
Desipramine—CHRM1—female reproductive system—ovarian cancer	0.000702	0.00938	CbGeAlD
Desipramine—SLC6A2—gonad—ovarian cancer	0.000695	0.00928	CbGeAlD
Desipramine—SLC22A1—vagina—ovarian cancer	0.000685	0.00916	CbGeAlD
Desipramine—SLC22A3—female gonad—ovarian cancer	0.000659	0.0088	CbGeAlD
Desipramine—SLC22A3—vagina—ovarian cancer	0.000655	0.00875	CbGeAlD
Desipramine—SLC22A5—endometrium—ovarian cancer	0.000636	0.00849	CbGeAlD
Desipramine—CHRM3—female reproductive system—ovarian cancer	0.000628	0.00839	CbGeAlD
Desipramine—SLC6A3—testis—ovarian cancer	0.000621	0.00829	CbGeAlD
Desipramine—SLC6A2—female reproductive system—ovarian cancer	0.000621	0.00829	CbGeAlD
Desipramine—HTR2A—embryo—ovarian cancer	0.000615	0.00822	CbGeAlD
Desipramine—HRH1—epithelium—ovarian cancer	0.000601	0.00803	CbGeAlD
Desipramine—HRH1—uterine cervix—ovarian cancer	0.000596	0.00796	CbGeAlD
Desipramine—SLC22A3—testis—ovarian cancer	0.000584	0.00781	CbGeAlD
Desipramine—CHRM3—female gonad—ovarian cancer	0.000572	0.00764	CbGeAlD
Desipramine—HRH1—decidua—ovarian cancer	0.000568	0.00759	CbGeAlD
Desipramine—HRH1—endometrium—ovarian cancer	0.000539	0.0072	CbGeAlD
Desipramine—CYP2C19—vagina—ovarian cancer	0.000528	0.00706	CbGeAlD
Desipramine—SLC22A5—female reproductive system—ovarian cancer	0.000527	0.00703	CbGeAlD
Desipramine—CYP2B6—gonad—ovarian cancer	0.000512	0.00684	CbGeAlD
Desipramine—CHRM3—testis—ovarian cancer	0.000507	0.00677	CbGeAlD
Desipramine—HTR2A—epithelium—ovarian cancer	0.000502	0.00671	CbGeAlD
Desipramine—SLC6A2—testis—ovarian cancer	0.000501	0.00669	CbGeAlD
Desipramine—ORM1—lymph node—ovarian cancer	0.000484	0.00646	CbGeAlD
Desipramine—SLC22A5—female gonad—ovarian cancer	0.000479	0.0064	CbGeAlD
Desipramine—SLC22A5—vagina—ovarian cancer	0.000476	0.00636	CbGeAlD
Desipramine—SLC22A4—lymph node—ovarian cancer	0.000466	0.00622	CbGeAlD
Desipramine—CYP2B6—female reproductive system—ovarian cancer	0.000457	0.00611	CbGeAlD
Desipramine—DRD2—testis—ovarian cancer	0.000456	0.0061	CbGeAlD
Desipramine—HRH1—female reproductive system—ovarian cancer	0.000447	0.00597	CbGeAlD
Desipramine—CYP2E1—female reproductive system—ovarian cancer	0.000429	0.00573	CbGeAlD
Desipramine—SLC22A5—testis—ovarian cancer	0.000425	0.00568	CbGeAlD
Desipramine—SLC22A3—lymph node—ovarian cancer	0.000424	0.00566	CbGeAlD
Desipramine—ABCB1—myometrium—ovarian cancer	0.000419	0.0056	CbGeAlD
Desipramine—HTR2A—gonad—ovarian cancer	0.000418	0.00558	CbGeAlD
Desipramine—CYP2B6—vagina—ovarian cancer	0.000414	0.00553	CbGeAlD
Desipramine—HRH1—female gonad—ovarian cancer	0.000406	0.00543	CbGeAlD
Desipramine—HRH1—vagina—ovarian cancer	0.000404	0.0054	CbGeAlD
Desipramine—ABCB1—embryo—ovarian cancer	0.000403	0.00539	CbGeAlD
Desipramine—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.000401	0.0025	CcSEcCtD
Desipramine—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.000401	0.0025	CcSEcCtD
Desipramine—Decreased appetite—Melphalan—ovarian cancer	0.0004	0.0025	CcSEcCtD
Desipramine—Fatigue—Melphalan—ovarian cancer	0.000397	0.00248	CcSEcCtD
Desipramine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000394	0.00246	CcSEcCtD
Desipramine—Tachycardia—Vinorelbine—ovarian cancer	0.000393	0.00245	CcSEcCtD
Desipramine—Feeling abnormal—Topotecan—ovarian cancer	0.000387	0.00242	CcSEcCtD
Desipramine—Anorexia—Vinorelbine—ovarian cancer	0.000383	0.00239	CcSEcCtD
Desipramine—Asthenia—Chlorambucil—ovarian cancer	0.000379	0.00237	CcSEcCtD
Desipramine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000379	0.00236	CcSEcCtD
Desipramine—Hypotension—Vinorelbine—ovarian cancer	0.000376	0.00235	CcSEcCtD
Desipramine—Pruritus—Chlorambucil—ovarian cancer	0.000374	0.00233	CcSEcCtD
Desipramine—Urticaria—Topotecan—ovarian cancer	0.000374	0.00233	CcSEcCtD
Desipramine—HTR2A—female reproductive system—ovarian cancer	0.000373	0.00498	CbGeAlD
Desipramine—Abdominal pain—Topotecan—ovarian cancer	0.000372	0.00232	CcSEcCtD
Desipramine—Body temperature increased—Topotecan—ovarian cancer	0.000372	0.00232	CcSEcCtD
Desipramine—CYP2B6—testis—ovarian cancer	0.000369	0.00493	CbGeAlD
Desipramine—Weight increased—Docetaxel—ovarian cancer	0.000367	0.00229	CcSEcCtD
Desipramine—Urticaria—Melphalan—ovarian cancer	0.000366	0.00228	CcSEcCtD
Desipramine—SLC6A2—lymph node—ovarian cancer	0.000363	0.00485	CbGeAlD
Desipramine—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.000362	0.00226	CcSEcCtD
Desipramine—Diarrhoea—Chlorambucil—ovarian cancer	0.000361	0.00226	CcSEcCtD
Desipramine—Paraesthesia—Vinorelbine—ovarian cancer	0.000361	0.00225	CcSEcCtD
Desipramine—HRH1—testis—ovarian cancer	0.00036	0.00481	CbGeAlD
Desipramine—Tinnitus—Paclitaxel—ovarian cancer	0.000355	0.00222	CcSEcCtD
Desipramine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000354	0.00221	CcSEcCtD
Desipramine—Flushing—Paclitaxel—ovarian cancer	0.000353	0.00221	CcSEcCtD
Desipramine—Myocardial infarction—Docetaxel—ovarian cancer	0.000352	0.0022	CcSEcCtD
Desipramine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000352	0.0022	CcSEcCtD
Desipramine—Vascular purpura—Epirubicin—ovarian cancer	0.000352	0.0022	CcSEcCtD
Desipramine—Stomatitis—Docetaxel—ovarian cancer	0.00035	0.00219	CcSEcCtD
Desipramine—Jaundice—Docetaxel—ovarian cancer	0.00035	0.00219	CcSEcCtD
Desipramine—Decreased appetite—Vinorelbine—ovarian cancer	0.00035	0.00218	CcSEcCtD
Desipramine—Fatigue—Vinorelbine—ovarian cancer	0.000347	0.00216	CcSEcCtD
Desipramine—CYP2E1—testis—ovarian cancer	0.000346	0.00463	CbGeAlD
Desipramine—CYP3A4—female reproductive system—ovarian cancer	0.000345	0.00461	CbGeAlD
Desipramine—Constipation—Vinorelbine—ovarian cancer	0.000344	0.00215	CcSEcCtD
Desipramine—Arrhythmia—Paclitaxel—ovarian cancer	0.00034	0.00212	CcSEcCtD
Desipramine—CYP2D6—female reproductive system—ovarian cancer	0.00034	0.00454	CbGeAlD
Desipramine—Asthenia—Topotecan—ovarian cancer	0.000337	0.00211	CcSEcCtD
Desipramine—HTR2A—vagina—ovarian cancer	0.000337	0.00451	CbGeAlD
Desipramine—Alopecia—Paclitaxel—ovarian cancer	0.000337	0.0021	CcSEcCtD
Desipramine—Vomiting—Chlorambucil—ovarian cancer	0.000336	0.0021	CcSEcCtD
Desipramine—Agranulocytosis—Docetaxel—ovarian cancer	0.000336	0.00209	CcSEcCtD
Desipramine—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.000335	0.00209	CcSEcCtD
Desipramine—Pruritus—Topotecan—ovarian cancer	0.000333	0.00208	CcSEcCtD
Desipramine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000331	0.00207	CcSEcCtD
Desipramine—Asthenia—Melphalan—ovarian cancer	0.00033	0.00206	CcSEcCtD
Desipramine—ABCB1—epithelium—ovarian cancer	0.000329	0.0044	CbGeAlD
Desipramine—Purpura—Epirubicin—ovarian cancer	0.000327	0.00204	CcSEcCtD
Desipramine—ABCB1—uterine cervix—ovarian cancer	0.000326	0.00436	CbGeAlD
Desipramine—Pruritus—Melphalan—ovarian cancer	0.000326	0.00203	CcSEcCtD
Desipramine—Vascular purpura—Doxorubicin—ovarian cancer	0.000326	0.00203	CcSEcCtD
Desipramine—Dysgeusia—Paclitaxel—ovarian cancer	0.000325	0.00203	CcSEcCtD
Desipramine—Hepatitis—Docetaxel—ovarian cancer	0.000323	0.00201	CcSEcCtD
Desipramine—Diarrhoea—Topotecan—ovarian cancer	0.000322	0.00201	CcSEcCtD
Desipramine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000321	0.002	CcSEcCtD
Desipramine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000321	0.002	CcSEcCtD
Desipramine—Urticaria—Vinorelbine—ovarian cancer	0.00032	0.00199	CcSEcCtD
Desipramine—Abdominal pain—Vinorelbine—ovarian cancer	0.000318	0.00198	CcSEcCtD
Desipramine—Body temperature increased—Vinorelbine—ovarian cancer	0.000318	0.00198	CcSEcCtD
Desipramine—Diarrhoea—Melphalan—ovarian cancer	0.000315	0.00197	CcSEcCtD
Desipramine—Nausea—Chlorambucil—ovarian cancer	0.000314	0.00196	CcSEcCtD
Desipramine—Vision blurred—Paclitaxel—ovarian cancer	0.000312	0.00195	CcSEcCtD
Desipramine—Dizziness—Topotecan—ovarian cancer	0.000311	0.00194	CcSEcCtD
Desipramine—ABCB1—decidua—ovarian cancer	0.000311	0.00415	CbGeAlD
Desipramine—Tremor—Paclitaxel—ovarian cancer	0.000311	0.00194	CcSEcCtD
Desipramine—CYP2D6—female gonad—ovarian cancer	0.000309	0.00413	CbGeAlD
Desipramine—SLC22A5—lymph node—ovarian cancer	0.000308	0.00412	CbGeAlD
Desipramine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000308	0.00192	CcSEcCtD
Desipramine—Agitation—Paclitaxel—ovarian cancer	0.000305	0.0019	CcSEcCtD
Desipramine—Purpura—Doxorubicin—ovarian cancer	0.000302	0.00189	CcSEcCtD
Desipramine—HTR2A—testis—ovarian cancer	0.000301	0.00402	CbGeAlD
Desipramine—Flushing—Docetaxel—ovarian cancer	0.0003	0.00187	CcSEcCtD
Desipramine—Vomiting—Topotecan—ovarian cancer	0.000299	0.00187	CcSEcCtD
Desipramine—Malaise—Paclitaxel—ovarian cancer	0.000299	0.00187	CcSEcCtD
Desipramine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000297	0.00185	CcSEcCtD
Desipramine—Rash—Topotecan—ovarian cancer	0.000296	0.00185	CcSEcCtD
Desipramine—Dermatitis—Topotecan—ovarian cancer	0.000296	0.00185	CcSEcCtD
Desipramine—Ataxia—Epirubicin—ovarian cancer	0.000296	0.00185	CcSEcCtD
Desipramine—ABCB1—endometrium—ovarian cancer	0.000295	0.00394	CbGeAlD
Desipramine—Headache—Topotecan—ovarian cancer	0.000295	0.00184	CcSEcCtD
Desipramine—Palpitations—Paclitaxel—ovarian cancer	0.000293	0.00183	CcSEcCtD
Desipramine—Vomiting—Melphalan—ovarian cancer	0.000293	0.00183	CcSEcCtD
Desipramine—Liver function test abnormal—Epirubicin—ovarian cancer	0.000291	0.00181	CcSEcCtD
Desipramine—Rash—Melphalan—ovarian cancer	0.00029	0.00181	CcSEcCtD
Desipramine—Dermatitis—Melphalan—ovarian cancer	0.00029	0.00181	CcSEcCtD
Desipramine—Asthenia—Vinorelbine—ovarian cancer	0.000289	0.0018	CcSEcCtD
Desipramine—Arrhythmia—Docetaxel—ovarian cancer	0.000288	0.0018	CcSEcCtD
Desipramine—Convulsion—Paclitaxel—ovarian cancer	0.000287	0.00179	CcSEcCtD
Desipramine—Hypertension—Paclitaxel—ovarian cancer	0.000286	0.00179	CcSEcCtD
Desipramine—Alopecia—Docetaxel—ovarian cancer	0.000285	0.00178	CcSEcCtD
Desipramine—Pruritus—Vinorelbine—ovarian cancer	0.000285	0.00178	CcSEcCtD
Desipramine—Anxiety—Paclitaxel—ovarian cancer	0.000281	0.00176	CcSEcCtD
Desipramine—Nausea—Topotecan—ovarian cancer	0.000279	0.00174	CcSEcCtD
Desipramine—Discomfort—Paclitaxel—ovarian cancer	0.000279	0.00174	CcSEcCtD
Desipramine—Dry mouth—Paclitaxel—ovarian cancer	0.000276	0.00172	CcSEcCtD
Desipramine—Diarrhoea—Vinorelbine—ovarian cancer	0.000275	0.00172	CcSEcCtD
Desipramine—Dysgeusia—Docetaxel—ovarian cancer	0.000275	0.00172	CcSEcCtD
Desipramine—CYP2D6—testis—ovarian cancer	0.000274	0.00366	CbGeAlD
Desipramine—Ataxia—Doxorubicin—ovarian cancer	0.000274	0.00171	CcSEcCtD
Desipramine—ABCB1—gonad—ovarian cancer	0.000274	0.00366	CbGeAlD
Desipramine—Nausea—Melphalan—ovarian cancer	0.000273	0.00171	CcSEcCtD
Desipramine—Confusional state—Paclitaxel—ovarian cancer	0.000273	0.0017	CcSEcCtD
Desipramine—ABCB1—uterus—ovarian cancer	0.000272	0.00363	CbGeAlD
Desipramine—Oedema—Paclitaxel—ovarian cancer	0.000271	0.00169	CcSEcCtD
Desipramine—Eosinophilia—Epirubicin—ovarian cancer	0.000269	0.00168	CcSEcCtD
Desipramine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000269	0.00168	CcSEcCtD
Desipramine—Dizziness—Vinorelbine—ovarian cancer	0.000266	0.00166	CcSEcCtD
Desipramine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000265	0.00165	CcSEcCtD
Desipramine—Tachycardia—Paclitaxel—ovarian cancer	0.000264	0.00165	CcSEcCtD
Desipramine—HRH1—lymph node—ovarian cancer	0.000261	0.00349	CbGeAlD
Desipramine—Anorexia—Paclitaxel—ovarian cancer	0.000258	0.00161	CcSEcCtD
Desipramine—Vomiting—Vinorelbine—ovarian cancer	0.000256	0.0016	CcSEcCtD
Desipramine—Rash—Vinorelbine—ovarian cancer	0.000254	0.00158	CcSEcCtD
Desipramine—Dermatitis—Vinorelbine—ovarian cancer	0.000253	0.00158	CcSEcCtD
Desipramine—Hypotension—Paclitaxel—ovarian cancer	0.000253	0.00158	CcSEcCtD
Desipramine—Headache—Vinorelbine—ovarian cancer	0.000252	0.00157	CcSEcCtD
Desipramine—Pollakiuria—Epirubicin—ovarian cancer	0.000251	0.00157	CcSEcCtD
Desipramine—Eosinophilia—Doxorubicin—ovarian cancer	0.000249	0.00156	CcSEcCtD
Desipramine—Palpitations—Docetaxel—ovarian cancer	0.000248	0.00155	CcSEcCtD
Desipramine—Weight increased—Epirubicin—ovarian cancer	0.000248	0.00154	CcSEcCtD
Desipramine—Insomnia—Paclitaxel—ovarian cancer	0.000245	0.00153	CcSEcCtD
Desipramine—ABCB1—female reproductive system—ovarian cancer	0.000244	0.00327	CbGeAlD
Desipramine—Convulsion—Docetaxel—ovarian cancer	0.000243	0.00152	CcSEcCtD
Desipramine—Paraesthesia—Paclitaxel—ovarian cancer	0.000243	0.00152	CcSEcCtD
Desipramine—Hypertension—Docetaxel—ovarian cancer	0.000243	0.00151	CcSEcCtD
Desipramine—Drowsiness—Epirubicin—ovarian cancer	0.000243	0.00151	CcSEcCtD
Desipramine—Protriptyline—ABCB1—ovarian cancer	0.000241	0.177	CrCbGaD
Desipramine—Somnolence—Paclitaxel—ovarian cancer	0.000241	0.0015	CcSEcCtD
Desipramine—Nausea—Vinorelbine—ovarian cancer	0.000239	0.00149	CcSEcCtD
Desipramine—Dyspepsia—Paclitaxel—ovarian cancer	0.000238	0.00149	CcSEcCtD
Desipramine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000238	0.00148	CcSEcCtD
Desipramine—Jaundice—Epirubicin—ovarian cancer	0.000236	0.00148	CcSEcCtD
Desipramine—Stomatitis—Epirubicin—ovarian cancer	0.000236	0.00148	CcSEcCtD
Desipramine—Decreased appetite—Paclitaxel—ovarian cancer	0.000235	0.00147	CcSEcCtD
Desipramine—Dry mouth—Docetaxel—ovarian cancer	0.000234	0.00146	CcSEcCtD
Desipramine—Fatigue—Paclitaxel—ovarian cancer	0.000233	0.00146	CcSEcCtD
Desipramine—Pollakiuria—Doxorubicin—ovarian cancer	0.000233	0.00145	CcSEcCtD
Desipramine—Constipation—Paclitaxel—ovarian cancer	0.000231	0.00144	CcSEcCtD
Desipramine—Confusional state—Docetaxel—ovarian cancer	0.000231	0.00144	CcSEcCtD
Desipramine—ABCB1—bone marrow—ovarian cancer	0.000231	0.00308	CbGeAlD
Desipramine—Oedema—Docetaxel—ovarian cancer	0.000229	0.00143	CcSEcCtD
Desipramine—Weight increased—Doxorubicin—ovarian cancer	0.000229	0.00143	CcSEcCtD
Desipramine—Agranulocytosis—Epirubicin—ovarian cancer	0.000226	0.00141	CcSEcCtD
Desipramine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000225	0.0014	CcSEcCtD
Desipramine—Drowsiness—Doxorubicin—ovarian cancer	0.000224	0.0014	CcSEcCtD
Desipramine—Tachycardia—Docetaxel—ovarian cancer	0.000224	0.0014	CcSEcCtD
Desipramine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000223	0.00139	CcSEcCtD
Desipramine—ABCB1—female gonad—ovarian cancer	0.000222	0.00297	CbGeAlD
Desipramine—ABCB1—vagina—ovarian cancer	0.000221	0.00295	CbGeAlD
Desipramine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00022	0.00137	CcSEcCtD
Desipramine—Stomatitis—Doxorubicin—ovarian cancer	0.000219	0.00137	CcSEcCtD
Desipramine—Jaundice—Doxorubicin—ovarian cancer	0.000219	0.00137	CcSEcCtD
Desipramine—Anorexia—Docetaxel—ovarian cancer	0.000219	0.00136	CcSEcCtD
Desipramine—Hepatitis—Epirubicin—ovarian cancer	0.000218	0.00136	CcSEcCtD
Desipramine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000217	0.00135	CcSEcCtD
Desipramine—Urticaria—Paclitaxel—ovarian cancer	0.000215	0.00134	CcSEcCtD
Desipramine—Hypotension—Docetaxel—ovarian cancer	0.000214	0.00134	CcSEcCtD
Desipramine—Abdominal pain—Paclitaxel—ovarian cancer	0.000214	0.00133	CcSEcCtD
Desipramine—Body temperature increased—Paclitaxel—ovarian cancer	0.000214	0.00133	CcSEcCtD
Desipramine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000209	0.00131	CcSEcCtD
Desipramine—Insomnia—Docetaxel—ovarian cancer	0.000207	0.00129	CcSEcCtD
Desipramine—Paraesthesia—Docetaxel—ovarian cancer	0.000206	0.00129	CcSEcCtD
Desipramine—Somnolence—Docetaxel—ovarian cancer	0.000204	0.00127	CcSEcCtD
Desipramine—Tinnitus—Epirubicin—ovarian cancer	0.000203	0.00127	CcSEcCtD
Desipramine—Flushing—Epirubicin—ovarian cancer	0.000202	0.00126	CcSEcCtD
Desipramine—Dyspepsia—Docetaxel—ovarian cancer	0.000202	0.00126	CcSEcCtD
Desipramine—Hepatitis—Doxorubicin—ovarian cancer	0.000201	0.00126	CcSEcCtD
Desipramine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.0002	0.00125	CcSEcCtD
Desipramine—Decreased appetite—Docetaxel—ovarian cancer	0.000199	0.00124	CcSEcCtD
Desipramine—Fatigue—Docetaxel—ovarian cancer	0.000198	0.00123	CcSEcCtD
Desipramine—ABCB1—testis—ovarian cancer	0.000197	0.00264	CbGeAlD
Desipramine—Constipation—Docetaxel—ovarian cancer	0.000196	0.00122	CcSEcCtD
Desipramine—Arrhythmia—Epirubicin—ovarian cancer	0.000195	0.00121	CcSEcCtD
Desipramine—Asthenia—Paclitaxel—ovarian cancer	0.000194	0.00121	CcSEcCtD
Desipramine—Alopecia—Epirubicin—ovarian cancer	0.000192	0.0012	CcSEcCtD
Desipramine—Pruritus—Paclitaxel—ovarian cancer	0.000191	0.00119	CcSEcCtD
Desipramine—Feeling abnormal—Docetaxel—ovarian cancer	0.000189	0.00118	CcSEcCtD
Desipramine—Tinnitus—Doxorubicin—ovarian cancer	0.000188	0.00117	CcSEcCtD
Desipramine—Flushing—Doxorubicin—ovarian cancer	0.000187	0.00117	CcSEcCtD
Desipramine—Dysgeusia—Epirubicin—ovarian cancer	0.000186	0.00116	CcSEcCtD
Desipramine—Diarrhoea—Paclitaxel—ovarian cancer	0.000185	0.00116	CcSEcCtD
Desipramine—Body temperature increased—Docetaxel—ovarian cancer	0.000181	0.00113	CcSEcCtD
Desipramine—Abdominal pain—Docetaxel—ovarian cancer	0.000181	0.00113	CcSEcCtD
Desipramine—Arrhythmia—Doxorubicin—ovarian cancer	0.00018	0.00112	CcSEcCtD
Desipramine—Dizziness—Paclitaxel—ovarian cancer	0.000179	0.00112	CcSEcCtD
Desipramine—Vision blurred—Epirubicin—ovarian cancer	0.000179	0.00111	CcSEcCtD
Desipramine—Epinastine—ABCB1—ovarian cancer	0.000178	0.131	CrCbGaD
Desipramine—Alopecia—Doxorubicin—ovarian cancer	0.000178	0.00111	CcSEcCtD
Desipramine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000176	0.0011	CcSEcCtD
Desipramine—Agitation—Epirubicin—ovarian cancer	0.000174	0.00109	CcSEcCtD
Desipramine—Vomiting—Paclitaxel—ovarian cancer	0.000172	0.00107	CcSEcCtD
Desipramine—Dysgeusia—Doxorubicin—ovarian cancer	0.000172	0.00107	CcSEcCtD
Desipramine—Malaise—Epirubicin—ovarian cancer	0.000171	0.00107	CcSEcCtD
Desipramine—Rash—Paclitaxel—ovarian cancer	0.000171	0.00106	CcSEcCtD
Desipramine—Dermatitis—Paclitaxel—ovarian cancer	0.00017	0.00106	CcSEcCtD
Desipramine—Headache—Paclitaxel—ovarian cancer	0.000169	0.00106	CcSEcCtD
Desipramine—Palpitations—Epirubicin—ovarian cancer	0.000167	0.00105	CcSEcCtD
Desipramine—Vision blurred—Doxorubicin—ovarian cancer	0.000165	0.00103	CcSEcCtD
Desipramine—Asthenia—Docetaxel—ovarian cancer	0.000165	0.00103	CcSEcCtD
Desipramine—Convulsion—Epirubicin—ovarian cancer	0.000164	0.00102	CcSEcCtD
Desipramine—Hypertension—Epirubicin—ovarian cancer	0.000164	0.00102	CcSEcCtD
Desipramine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000163	0.00102	CcSEcCtD
Desipramine—Pruritus—Docetaxel—ovarian cancer	0.000162	0.00101	CcSEcCtD
Desipramine—Agitation—Doxorubicin—ovarian cancer	0.000161	0.00101	CcSEcCtD
Desipramine—Anxiety—Epirubicin—ovarian cancer	0.000161	0.001	CcSEcCtD
Desipramine—Nausea—Paclitaxel—ovarian cancer	0.000161	0.001	CcSEcCtD
Desipramine—Discomfort—Epirubicin—ovarian cancer	0.000159	0.000995	CcSEcCtD
Desipramine—Malaise—Doxorubicin—ovarian cancer	0.000158	0.000987	CcSEcCtD
Desipramine—Dry mouth—Epirubicin—ovarian cancer	0.000158	0.000985	CcSEcCtD
Desipramine—Diarrhoea—Docetaxel—ovarian cancer	0.000157	0.000979	CcSEcCtD
Desipramine—Confusional state—Epirubicin—ovarian cancer	0.000156	0.000973	CcSEcCtD
Desipramine—Palpitations—Doxorubicin—ovarian cancer	0.000155	0.000967	CcSEcCtD
Desipramine—Oedema—Epirubicin—ovarian cancer	0.000155	0.000965	CcSEcCtD
Desipramine—Maprotiline—ABCB1—ovarian cancer	0.000153	0.113	CrCbGaD
Desipramine—Convulsion—Doxorubicin—ovarian cancer	0.000152	0.000948	CcSEcCtD
Desipramine—Dizziness—Docetaxel—ovarian cancer	0.000152	0.000946	CcSEcCtD
Desipramine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000151	0.000945	CcSEcCtD
Desipramine—Hypertension—Doxorubicin—ovarian cancer	0.000151	0.000945	CcSEcCtD
Desipramine—Tachycardia—Epirubicin—ovarian cancer	0.000151	0.000942	CcSEcCtD
Desipramine—Anxiety—Doxorubicin—ovarian cancer	0.000149	0.000929	CcSEcCtD
Desipramine—Discomfort—Doxorubicin—ovarian cancer	0.000148	0.000921	CcSEcCtD
Desipramine—Anorexia—Epirubicin—ovarian cancer	0.000147	0.00092	CcSEcCtD
Desipramine—Dry mouth—Doxorubicin—ovarian cancer	0.000146	0.000911	CcSEcCtD
Desipramine—Vomiting—Docetaxel—ovarian cancer	0.000146	0.00091	CcSEcCtD
Desipramine—Rash—Docetaxel—ovarian cancer	0.000145	0.000902	CcSEcCtD
Desipramine—Hypotension—Epirubicin—ovarian cancer	0.000145	0.000902	CcSEcCtD
Desipramine—Dermatitis—Docetaxel—ovarian cancer	0.000144	0.000902	CcSEcCtD
Desipramine—Confusional state—Doxorubicin—ovarian cancer	0.000144	0.000901	CcSEcCtD
Desipramine—Headache—Docetaxel—ovarian cancer	0.000144	0.000897	CcSEcCtD
Desipramine—Oedema—Doxorubicin—ovarian cancer	0.000143	0.000893	CcSEcCtD
Desipramine—ABCB1—lymph node—ovarian cancer	0.000143	0.00191	CbGeAlD
Desipramine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00014	0.000875	CcSEcCtD
Desipramine—Insomnia—Epirubicin—ovarian cancer	0.00014	0.000873	CcSEcCtD
Desipramine—Tachycardia—Doxorubicin—ovarian cancer	0.00014	0.000872	CcSEcCtD
Desipramine—Paraesthesia—Epirubicin—ovarian cancer	0.000139	0.000867	CcSEcCtD
Desipramine—Somnolence—Epirubicin—ovarian cancer	0.000138	0.000858	CcSEcCtD
Desipramine—Anorexia—Doxorubicin—ovarian cancer	0.000136	0.000851	CcSEcCtD
Desipramine—Nausea—Docetaxel—ovarian cancer	0.000136	0.00085	CcSEcCtD
Desipramine—Dyspepsia—Epirubicin—ovarian cancer	0.000136	0.00085	CcSEcCtD
Desipramine—Decreased appetite—Epirubicin—ovarian cancer	0.000134	0.000839	CcSEcCtD
Desipramine—Triflupromazine—ABCB1—ovarian cancer	0.000134	0.0987	CrCbGaD
Desipramine—Hypotension—Doxorubicin—ovarian cancer	0.000134	0.000835	CcSEcCtD
Desipramine—Fatigue—Epirubicin—ovarian cancer	0.000133	0.000832	CcSEcCtD
Desipramine—Constipation—Epirubicin—ovarian cancer	0.000132	0.000826	CcSEcCtD
Desipramine—Insomnia—Doxorubicin—ovarian cancer	0.000129	0.000808	CcSEcCtD
Desipramine—Paraesthesia—Doxorubicin—ovarian cancer	0.000129	0.000802	CcSEcCtD
Desipramine—Feeling abnormal—Epirubicin—ovarian cancer	0.000127	0.000796	CcSEcCtD
Desipramine—Somnolence—Doxorubicin—ovarian cancer	0.000127	0.000794	CcSEcCtD
Desipramine—Dyspepsia—Doxorubicin—ovarian cancer	0.000126	0.000786	CcSEcCtD
Desipramine—Decreased appetite—Doxorubicin—ovarian cancer	0.000124	0.000777	CcSEcCtD
Desipramine—Fatigue—Doxorubicin—ovarian cancer	0.000123	0.00077	CcSEcCtD
Desipramine—Urticaria—Epirubicin—ovarian cancer	0.000123	0.000767	CcSEcCtD
Desipramine—Constipation—Doxorubicin—ovarian cancer	0.000122	0.000764	CcSEcCtD
Desipramine—Abdominal pain—Epirubicin—ovarian cancer	0.000122	0.000763	CcSEcCtD
Desipramine—Body temperature increased—Epirubicin—ovarian cancer	0.000122	0.000763	CcSEcCtD
Desipramine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000118	0.000736	CcSEcCtD
Desipramine—Urticaria—Doxorubicin—ovarian cancer	0.000114	0.00071	CcSEcCtD
Desipramine—Abdominal pain—Doxorubicin—ovarian cancer	0.000113	0.000706	CcSEcCtD
Desipramine—Body temperature increased—Doxorubicin—ovarian cancer	0.000113	0.000706	CcSEcCtD
Desipramine—Carbamazepine—ABCB1—ovarian cancer	0.000112	0.0824	CrCbGaD
Desipramine—Asthenia—Epirubicin—ovarian cancer	0.000111	0.000693	CcSEcCtD
Desipramine—Pruritus—Epirubicin—ovarian cancer	0.000109	0.000683	CcSEcCtD
Desipramine—Diarrhoea—Epirubicin—ovarian cancer	0.000106	0.000661	CcSEcCtD
Desipramine—Asthenia—Doxorubicin—ovarian cancer	0.000103	0.000641	CcSEcCtD
Desipramine—Dizziness—Epirubicin—ovarian cancer	0.000102	0.000638	CcSEcCtD
Desipramine—Pruritus—Doxorubicin—ovarian cancer	0.000101	0.000632	CcSEcCtD
Desipramine—Vomiting—Epirubicin—ovarian cancer	9.84e-05	0.000614	CcSEcCtD
Desipramine—Diarrhoea—Doxorubicin—ovarian cancer	9.79e-05	0.000611	CcSEcCtD
Desipramine—Rash—Epirubicin—ovarian cancer	9.75e-05	0.000609	CcSEcCtD
Desipramine—Dermatitis—Epirubicin—ovarian cancer	9.74e-05	0.000608	CcSEcCtD
Desipramine—Headache—Epirubicin—ovarian cancer	9.69e-05	0.000605	CcSEcCtD
Desipramine—Dizziness—Doxorubicin—ovarian cancer	9.46e-05	0.000591	CcSEcCtD
Desipramine—Clomipramine—ABCB1—ovarian cancer	9.44e-05	0.0694	CrCbGaD
Desipramine—Nausea—Epirubicin—ovarian cancer	9.19e-05	0.000573	CcSEcCtD
Desipramine—Vomiting—Doxorubicin—ovarian cancer	9.1e-05	0.000568	CcSEcCtD
Desipramine—Rash—Doxorubicin—ovarian cancer	9.02e-05	0.000563	CcSEcCtD
Desipramine—Dermatitis—Doxorubicin—ovarian cancer	9.02e-05	0.000563	CcSEcCtD
Desipramine—Headache—Doxorubicin—ovarian cancer	8.97e-05	0.00056	CcSEcCtD
Desipramine—Trimipramine—ABCB1—ovarian cancer	8.68e-05	0.0639	CrCbGaD
Desipramine—Nausea—Doxorubicin—ovarian cancer	8.5e-05	0.000531	CcSEcCtD
Desipramine—Promethazine—ABCB1—ovarian cancer	8.36e-05	0.0615	CrCbGaD
Desipramine—Doxepin—ABCB1—ovarian cancer	8.27e-05	0.0609	CrCbGaD
Desipramine—Chlorpromazine—ABCB1—ovarian cancer	6.47e-05	0.0476	CrCbGaD
Desipramine—Imipramine—ABCB1—ovarian cancer	6.44e-05	0.0474	CrCbGaD
Desipramine—Amitriptyline—ABCB1—ovarian cancer	6.4e-05	0.0471	CrCbGaD
Desipramine—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	4.75e-06	4.85e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	4.75e-06	4.84e-05	CbGpPWpGaD
Desipramine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	4.75e-06	4.84e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	4.72e-06	4.82e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	4.72e-06	4.81e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—KRAS—ovarian cancer	4.72e-06	4.81e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	4.71e-06	4.81e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—STAT3—ovarian cancer	4.71e-06	4.8e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CASP3—ovarian cancer	4.7e-06	4.8e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	4.7e-06	4.79e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—IL2—ovarian cancer	4.7e-06	4.79e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—NRAS—ovarian cancer	4.69e-06	4.79e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CDKN1B—ovarian cancer	4.68e-06	4.78e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—IL6—ovarian cancer	4.67e-06	4.77e-05	CbGpPWpGaD
Desipramine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	4.67e-06	4.77e-05	CbGpPWpGaD
Desipramine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	4.66e-06	4.75e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	4.66e-06	4.75e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	4.65e-06	4.74e-05	CbGpPWpGaD
Desipramine—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	4.65e-06	4.74e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	4.64e-06	4.73e-05	CbGpPWpGaD
Desipramine—CHRM3—GPCR downstream signaling—AKT1—ovarian cancer	4.63e-06	4.72e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	4.63e-06	4.72e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IL2—ovarian cancer	4.62e-06	4.71e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CASP3—ovarian cancer	4.62e-06	4.71e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IL2—ovarian cancer	4.61e-06	4.7e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—STAT3—ovarian cancer	4.6e-06	4.7e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CASP3—ovarian cancer	4.6e-06	4.7e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	4.6e-06	4.69e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IL2—ovarian cancer	4.6e-06	4.69e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—NRAS—ovarian cancer	4.59e-06	4.68e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CASP3—ovarian cancer	4.59e-06	4.68e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—IL6—ovarian cancer	4.59e-06	4.68e-05	CbGpPWpGaD
Desipramine—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	4.59e-06	4.68e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IL2—ovarian cancer	4.58e-06	4.67e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CCND1—ovarian cancer	4.58e-06	4.67e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—IL6—ovarian cancer	4.57e-06	4.67e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—IL6—ovarian cancer	4.56e-06	4.65e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.55e-06	4.64e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	4.55e-06	4.64e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CASP3—ovarian cancer	4.54e-06	4.64e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IL2—ovarian cancer	4.54e-06	4.63e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	4.53e-06	4.62e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—PIK3CA—ovarian cancer	4.52e-06	4.62e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	4.52e-06	4.61e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—IL6—ovarian cancer	4.51e-06	4.61e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	4.5e-06	4.6e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	4.5e-06	4.59e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	4.5e-06	4.59e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CCND1—ovarian cancer	4.49e-06	4.59e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	4.49e-06	4.58e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CCND1—ovarian cancer	4.48e-06	4.57e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	4.48e-06	4.57e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	4.47e-06	4.56e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CCND1—ovarian cancer	4.47e-06	4.56e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	4.46e-06	4.55e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	4.45e-06	4.54e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	4.45e-06	4.54e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MMP9—ovarian cancer	4.44e-06	4.53e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	4.44e-06	4.53e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PTEN—ovarian cancer	4.44e-06	4.52e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	4.42e-06	4.51e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CTNNB1—ovarian cancer	4.42e-06	4.51e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PTEN—ovarian cancer	4.42e-06	4.51e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	4.4e-06	4.49e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	4.38e-06	4.47e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TP53—ovarian cancer	4.38e-06	4.47e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	4.37e-06	4.46e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MYC—ovarian cancer	4.37e-06	4.46e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MMP9—ovarian cancer	4.36e-06	4.45e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MMP9—ovarian cancer	4.35e-06	4.44e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	4.35e-06	4.44e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PTEN—ovarian cancer	4.34e-06	4.43e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.34e-06	4.43e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PTEN—ovarian cancer	4.34e-06	4.43e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MMP9—ovarian cancer	4.34e-06	4.42e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	4.33e-06	4.42e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CAV1—ovarian cancer	4.33e-06	4.42e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PTEN—ovarian cancer	4.32e-06	4.41e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	4.31e-06	4.4e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PTEN—ovarian cancer	4.31e-06	4.4e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	4.3e-06	4.39e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	4.29e-06	4.38e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MYC—ovarian cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	4.27e-06	4.35e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	4.24e-06	4.33e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	4.23e-06	4.32e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	4.22e-06	4.31e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.22e-06	4.31e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	4.22e-06	4.3e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	4.21e-06	4.29e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TP53—ovarian cancer	4.19e-06	4.28e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—HRAS—ovarian cancer	4.19e-06	4.27e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	4.18e-06	4.27e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—EGFR—ovarian cancer	4.18e-06	4.27e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MYC—ovarian cancer	4.18e-06	4.27e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	4.16e-06	4.25e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MYC—ovarian cancer	4.16e-06	4.24e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—TYMS—ovarian cancer	4.15e-06	4.23e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.14e-06	4.22e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.09e-06	4.18e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	4.09e-06	4.17e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	4.09e-06	4.17e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	4.07e-06	4.15e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	4.07e-06	4.15e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	4.04e-06	4.12e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—HRAS—ovarian cancer	4.01e-06	4.09e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—IL6—ovarian cancer	4.01e-06	4.09e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	3.99e-06	4.07e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—KRAS—ovarian cancer	3.95e-06	4.03e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—STAT3—ovarian cancer	3.95e-06	4.03e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.94e-06	4.02e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—NRAS—ovarian cancer	3.94e-06	4.02e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	3.94e-06	4.02e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	3.93e-06	4.01e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	3.92e-06	4e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	3.91e-06	3.98e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	3.89e-06	3.97e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	3.89e-06	3.97e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—STAT3—ovarian cancer	3.88e-06	3.96e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	3.88e-06	3.96e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.88e-06	3.96e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	3.88e-06	3.96e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—NRAS—ovarian cancer	3.87e-06	3.95e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—STAT3—ovarian cancer	3.87e-06	3.95e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	3.86e-06	3.94e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—NRAS—ovarian cancer	3.86e-06	3.94e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	3.86e-06	3.93e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—STAT3—ovarian cancer	3.86e-06	3.93e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—NRAS—ovarian cancer	3.85e-06	3.92e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	3.84e-06	3.92e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—IL6—ovarian cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	3.82e-06	3.89e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	3.81e-06	3.89e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.79e-06	3.86e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	3.78e-06	3.85e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	3.72e-06	3.79e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	3.71e-06	3.79e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	3.71e-06	3.78e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—AKT1—ovarian cancer	3.7e-06	3.77e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	3.7e-06	3.77e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	3.68e-06	3.76e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MYC—ovarian cancer	3.67e-06	3.75e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	3.65e-06	3.72e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PIK3CA—ovarian cancer	3.64e-06	3.71e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	3.63e-06	3.7e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MYC—ovarian cancer	3.61e-06	3.69e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MYC—ovarian cancer	3.61e-06	3.68e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MYC—ovarian cancer	3.59e-06	3.67e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	3.59e-06	3.66e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—EGFR—ovarian cancer	3.59e-06	3.66e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TP53—ovarian cancer	3.59e-06	3.66e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MYC—ovarian cancer	3.58e-06	3.65e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	3.57e-06	3.64e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	3.55e-06	3.62e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MYC—ovarian cancer	3.55e-06	3.62e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—AKT1—ovarian cancer	3.54e-06	3.61e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	3.53e-06	3.61e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	3.53e-06	3.61e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	3.53e-06	3.6e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	3.53e-06	3.6e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—EGFR—ovarian cancer	3.53e-06	3.6e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	3.52e-06	3.59e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—EGFR—ovarian cancer	3.52e-06	3.59e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TP53—ovarian cancer	3.51e-06	3.58e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	3.5e-06	3.58e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—EGFR—ovarian cancer	3.5e-06	3.57e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	3.47e-06	3.54e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	3.47e-06	3.54e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.47e-06	3.54e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—AKT1—ovarian cancer	3.45e-06	3.52e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TP53—ovarian cancer	3.43e-06	3.5e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	3.43e-06	3.5e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TP53—ovarian cancer	3.42e-06	3.49e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—KRAS—ovarian cancer	3.39e-06	3.46e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—HRAS—ovarian cancer	3.36e-06	3.43e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PTEN—ovarian cancer	3.35e-06	3.42e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CAV1—ovarian cancer	3.34e-06	3.41e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	3.34e-06	3.41e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—KRAS—ovarian cancer	3.33e-06	3.4e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—KRAS—ovarian cancer	3.32e-06	3.39e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—KRAS—ovarian cancer	3.31e-06	3.38e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—IL6—ovarian cancer	3.29e-06	3.35e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	3.28e-06	3.35e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	3.28e-06	3.34e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PTEN—ovarian cancer	3.27e-06	3.34e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	3.27e-06	3.33e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—AKT1—ovarian cancer	3.22e-06	3.28e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—IL6—ovarian cancer	3.22e-06	3.28e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—AKT1—ovarian cancer	3.17e-06	3.23e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—IL6—ovarian cancer	3.14e-06	3.21e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	3.13e-06	3.19e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—IL6—ovarian cancer	3.13e-06	3.19e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.12e-06	3.18e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PTEN—ovarian cancer	3.08e-06	3.14e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.07e-06	3.13e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PIK3CA—ovarian cancer	3.06e-06	3.13e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	3.06e-06	3.12e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	3.05e-06	3.11e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.04e-06	3.11e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	3.04e-06	3.1e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	3.03e-06	3.09e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.02e-06	3.08e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TP53—ovarian cancer	3.02e-06	3.08e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	3.01e-06	3.07e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—AKT1—ovarian cancer	2.97e-06	3.03e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TP53—ovarian cancer	2.97e-06	3.03e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—AKT1—ovarian cancer	2.97e-06	3.03e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TP53—ovarian cancer	2.96e-06	3.02e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TP53—ovarian cancer	2.95e-06	3.01e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TP53—ovarian cancer	2.94e-06	3e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TP53—ovarian cancer	2.91e-06	2.97e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	2.9e-06	2.96e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	2.89e-06	2.94e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—HRAS—ovarian cancer	2.88e-06	2.94e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	2.84e-06	2.89e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—HRAS—ovarian cancer	2.83e-06	2.89e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—HRAS—ovarian cancer	2.82e-06	2.88e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—HRAS—ovarian cancer	2.81e-06	2.87e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	2.79e-06	2.84e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—IL6—ovarian cancer	2.76e-06	2.82e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IL6—ovarian cancer	2.72e-06	2.77e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IL6—ovarian cancer	2.71e-06	2.76e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IL6—ovarian cancer	2.7e-06	2.76e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IL6—ovarian cancer	2.69e-06	2.75e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.68e-06	2.73e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IL6—ovarian cancer	2.67e-06	2.72e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PTEN—ovarian cancer	2.61e-06	2.66e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—AKT1—ovarian cancer	2.56e-06	2.61e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.55e-06	2.6e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.51e-06	2.56e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—AKT1—ovarian cancer	2.5e-06	2.55e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.5e-06	2.55e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—AKT1—ovarian cancer	2.49e-06	2.54e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—AKT1—ovarian cancer	2.48e-06	2.53e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	2.46e-06	2.51e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.33e-06	2.38e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.31e-06	2.35e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.17e-06	2.22e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTEN—ovarian cancer	2.02e-06	2.06e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—AKT1—ovarian cancer	1.93e-06	1.97e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—AKT1—ovarian cancer	1.89e-06	1.92e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.84e-06	1.88e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.78e-06	1.81e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.5e-06	1.54e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.42e-06	1.45e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.16e-06	1.18e-05	CbGpPWpGaD
